Identification of RP‐54745, an IL‐1 Inhibitor Displaying Anticancer Activities for KSHV‐Related Primary Effusion Lymphoma
Journal of Medical Virology · 2025-02 · 97 (2)
DOI: 10.1002/jmv.70200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 01.02.2025. Verfasst von Lu Dai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Lymphoma, Primary Effusion, Herpesvirus 8, Human, Interleukin-1, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIDCR NIH HHS.
Abstract (Originalsprache)
Kaposi's sarcoma‐associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including primary effusion lymphoma (PEL), usually seen in immunocompromised patients while lack of effective therapeutic options. Interleukin‐1 (IL‐1) family is a major mediator for inflammatory responses and has functional role in both innate and adaptive immunity. We previously showed high activation of multiple IL‐1 signaling molecules during KSHV latent and lytic stages, as well as in clinical samples from patients with KSHV‐related malignancies. In the current study, we identified RP‐54745, a potential antirheumatic compound as IL‐1 inhibitor, effectively repressed KSHV + PEL cell growth through inducing tumor cell apoptosis. By using an established PEL xenograft model, we found that RP‐54745 treatment suppressed tumor expansion in mice. Also, RP‐54745 treatment significantly reduced hyperinflammation in tumor microenvironment including myeloid cells and neutrophils infiltration, as well as blocking IL‐1 signaling molecules expression in vivo. In addition, our transcriptome analysis revealed novel cellular genes and mechanisms for anticancer activities of RP‐54745. Taken together, our data indicate targeting IL‐1 production and signaling may represent promising therapeutic strategies against these virus‐associated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Little Rock Central High School, Little Rock, Arkansas, USA.
- Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Department of Pathology & Laboratory Medicine, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, Louisiana, USA.
ORCID-Profile: Zhiqiang Qin
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NIDCR NIH HHS
- NIGMS NIH HHS
- The study was supported by the National Institutes of Health (R03DE031978, R21AI186566, R21AI175738, and R01AI184960), National Cancer Institute (R01CA261258),…
- National Institutes of Health
Zitieren
APA
Dai, L., Choudhary, A., Fan, J., Huang, L., Lin, Z., & Qin, Z. (2025). Identification of RP‐54745, an IL‐1 Inhibitor Displaying Anticancer Activities for KSHV‐Related Primary Effusion Lymphoma. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70200
Vancouver
Dai L, Choudhary A, Fan J, Huang L, Lin Z, Qin Z. Identification of RP‐54745, an IL‐1 Inhibitor Displaying Anticancer Activities for KSHV‐Related Primary Effusion Lymphoma. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70200
BibTeX
@article{Dai2025,
author = {Dai, Lu and Choudhary, Amrita and Fan, Jiaojiao and Huang, Lu and Lin, Zhen and Qin, Zhiqiang},
title = {Identification of RP‐54745, an IL‐1 Inhibitor Displaying Anticancer Activities for KSHV‐Related Primary Effusion Lymphoma},
journal = {Journal of Medical Virology},
year = {2025},
volume = {97},
number = {2},
doi = {10.1002/jmv.70200}
}
EUVIMED